Orchard Therapeutics has said it plans to file for approval for a gene therapy for the life-threatening rare disease metachromatic leukodystrophy (MLD) in Europe, after publishing new data.
The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, accepting a faster readout that should hasten development of the drug.
